Connect with us

Health

Trump budget draft ends Narcan program and other addiction measures.

Published

on

Trump budget draft ends Narcan program and other addiction measures.

The opioid overdose reversal medication commercially known as Narcan saves hundreds of thousands of lives a year and is routinely praised by public health experts for contributing to the continuing drop in opioid-related deaths. But the Trump administration plans to terminate a $56 million annual grant program that distributes doses and trains emergency responders in communities across the country to administer them, according to a draft budget proposal.

In the document, which outlines details of the drastic reorganization and shrinking planned for the Department of Health and Human Services, the grant is among many addiction prevention and treatment programs to be zeroed out.

States and local governments have other resources for obtaining doses of Narcan, which is also known by its generic name, naloxone. One of the main sources, a program of block grants for states to use to pay for various measures to combat opioid addiction, does not appear to have been cut.

But addiction specialists are worried about the symbolic as well as practical implications of shutting down a federal grant designated specifically for naloxone training and distribution.

“Reducing the funding for naloxone and overdose prevention sends the message that we would rather people who use drugs die than get the support they need and deserve,” said Dr. Melody Glenn, an addiction medicine physician and assistant professor at the University of Arizona, who monitors such programs along the state’s southern border.

Advertisement
At the scene of an emergency, first responders can hand out extra doses of Narcan and information about addiction recovery services.Credit…Arin Yoon for The New York Times

Neither the Department of Health and Human Services nor the White House’s drug policy office responded to requests for comment.

Although budget decisions are not finalized and could be adjusted, Dr. Glenn and others see the fact that the Trump administration has not even opened applications for new grants as another indication that the programs may be eliminated.

Other addiction-related grants on the chopping block include those offering treatment for pregnant and postpartum women; peer support programs typically run by people who are in recovery; a program called the “youth prevention and recovery initiative”; and programs that develop pain management protocols for emergency departments in lieu of opioids.

The federal health secretary, Robert F. Kennedy Jr., has long shown a passionate interest in addressing the drug crisis and has been outspoken about his own recovery from heroin addiction. The proposed elimination of addiction programs seems at odds with that goal. Last year, Mr. Kennedy’s presidential campaign produced a documentary that outlined federally supported pathways out of addiction.

The grants were awarded through the Substance Abuse and Mental Health Services Administration, an agency within the federal health department that would itself be eliminated under the draft budget proposal, though some of its programs would continue under a new entity, the Administration for a Healthy America.

Advertisement

In 2024, recipients of the naloxone grants, including cities, tribes and nonprofit groups, trained 66,000 police officers, fire fighters and emergency medical responders, and distributed over 282,500 naloxone kits, according to a spokesman for the substance abuse agency.

“Narcan has been kind of a godsend as far as opioid epidemics are concerned, and we certainly are in the middle of one now with fentanyl,” said Donald McNamara, who oversees naloxone procurement and training for the Los Angeles County Sheriff’s Department. “We need this funding source because it’s saving lives every day.”

Matthew Cushman, a fire department paramedic in Raytown, Mo., said that through the naloxone grant program, he had trained thousands of police officers, firefighters and emergency medical responders throughout Kansas City and western rural areas. The program provides trainees with pouches of naloxone to administer in the field plus “leave behind” kits with information about detox and treatment clinics.

Matthew Cushman, a paramedic in Raytown, Mo., has taught thousands of police officers, firefighters and emergency medical responders how to use Narcan.Credit…Arin Yoon for The New York Times

In 2023, federal figures started to show that national opioid deaths were finally declining, progress that many public health experts attribute in some measure to wider availability of the drug, which the Food and Drug Administration approved for over-the-counter sales that year.

Tennessee reports that between 2017 and 2024, 103,000 lives saved were directly attributable to naloxone. In Kentucky, which trains and supplies emergency medical workers in 68 rural communities, a health department spokeswoman noted that in 2023, overdose fatalities dropped by nearly 10 percent.

Advertisement

And though the focus of the Trump administration’s Office of National Drug Control Policy is weighted toward border policing and drug prosecutions, its priorities, released in an official statement this month, include the goal of expanding access to “lifesaving opioid overdose reversal medications like naloxone.”

“They immediately reference how much they want to support first responders and naloxone distribution,” said Rachel Winograd, director of the addiction science team at the University of Missouri-St. Louis, who oversees the state’s federally funded naloxone program. “Juxtaposing those statements of support with the proposed eliminations is extremely confusing.”

Mr. Cushman, the paramedic in Missouri, said that ending the naloxone grant program would not only cut off a source of the medication to emergency responders but would also stop classes that do significantly more than teach how to administer it.

His cited the insights offered by his co-instructor, Ray Rath, who is in recovery from heroin and is a certified peer support counselor. In training sessions, Mr. Rath recounts how, after a nasal spray of Narcan yanked him back from a heroin overdose, he found himself on the ground, looking up at police officers and emergency medical responders. They were snickering.

“Ah this junkie again, he’s just going to kill himself; we’re out here for no reason,” he recalled them saying.

Advertisement
Ray Rath, who is in recovery from heroin, leads naloxone trainings alongside Mr. Cushman, giving emergency responders the viewpoint of someone who was revived by the medication numerous times.Credit…Arin Yoon for The New York Times

Mr. Rath said he speaks with trainees about how the individuals they revive are “people that have an illness.”

“And once we start treating them like people, they feel like people,” he continued. “They feel cared about, and they want to make a change.”

He estimated that during the years he used opioids, naloxone revived him from overdoses at least 10 times. He has been in recovery for five years, a training instructor for the last three. He also works in homeless encampments in Kansas, offering services to people who use drugs. The back of his T-shirt reads: “Hope Dealer.”

Health

New Wegovy pill offers needle-free weight loss — but may not work for everyone

Published

on

New Wegovy pill offers needle-free weight loss — but may not work for everyone

NEWYou can now listen to Fox News articles!

The first oral GLP-1 medication for weight loss has been approved for use in the U.S.

The Wegovy pill, from drugmaker Novo Nordisk, was cleared by the Food and Drug Administration to reduce excess body weight, maintain long-term weight reduction and lower the risk of major cardiovascular events.

Approval of the once-daily 25mg semaglutide pill was based on the results of two clinical trials — the OASIS trial program and the SELECT trial.

WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS

Advertisement

The Wegovy pill demonstrated a mean weight loss of 16.6% in the OASIS 4 trial among adults who were obese or overweight and had one or more comorbidities (other medical conditions), according to a press release. In the same trial, one in three participants experienced 20% or greater weight loss.

The first oral GLP-1 medication for weight loss has been approved for use in the U.S. (iStock)

Novo Nordisk reported that the weight loss achieved with the pill is similar to that of injectable Wegovy and has a similar safety profile.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

“With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Mike Doustdar, president and CEO of Novo Nordisk, in the press release.

Advertisement

Novo Nordisk reported that the weight loss achieved with the pill is similar to that of injectable Wegovy and has a similar safety profile. (James Manning/PA Images via Getty Images)

“As the first oral GLP-1 treatment for people living with overweight or obesity, the Wegovy pill provides patients with a new, convenient treatment option that can help patients start or continue their weight-loss journey.”

POPULAR WEIGHT-LOSS DRUGS COULD TAKE THE EDGE OFF YOUR ALCOHOL BUZZ, STUDY FINDS

The oral GLP-1 is expected to launch in the U.S. in early January 2026. Novo Nordisk has also submitted oral semaglutide for obesity to the European Medicines Agency (EMA) and other regulatory authorities.

“Most side effects will be GI-related and should be similar to the injectable, such as nausea, vomiting and constipation,” an expert said. (iStock)

Advertisement

Dr. Sue Decotiis, a medical weight-loss doctor in New York City, confirmed in an interview with Fox News Digital that studies show oral Wegovy is comparable to the weekly injectable, just without the needles.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Although the pill may result in better compliance and ease of use, Decotiis warned that some patients may not absorb the medication through the gastrointestinal tract as well as with the injectable version due to individual idiosyncrasies in the body.

“Most side effects will be GI-related and should be similar to the injectable, such as nausea, vomiting and constipation,” she said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

“In my practice, I have found tirzepatide (Mounjaro and Zepbound) to yield more weight loss and fat loss than semaglutide by about 20%,” the doctor added. “This has been shown in studies, often [with] fewer side effects.”

More oral GLP-1s may be coming in 2026, according to Decotiis, including an Orforglipron application by Lilly and a new combination Novo Nordisk drug, which is pending approval later next year.

One expert warned that some patients may not absorb the medication through the gastrointestinal tract as well as with the injectable version. (iStock)

“There will be more new drugs available in the future that will be more effective for patients who are more insulin-resistant and have not responded as well to semaglutide and/or tirzepatide,” the doctor said. “This is great news, as novel drugs affecting more receptors mean better long-term results in more patients.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

As these medications become cheaper and easier to access, Decotiis emphasized that keeping up with healthy lifestyle habits — including proper nutrition with sufficient protein and fiber, as well as increased hydration — is essential to ensuring lasting results.

CLICK HERE FOR MORE HEALTH STORIES

“If not, patients will regain weight and could lose muscle and not enough body fat,” she said.

Fox News Digital reached out to Novo Nordisk for comment.

Advertisement
Continue Reading

Health

Common household chemicals linked to increased risk of serious neurological condition

Published

on

Common household chemicals linked to increased risk of serious neurological condition

NEWYou can now listen to Fox News articles!

A study from Sweden’s Uppsala University discovered a link between microplastics and multiple sclerosis (MS).

The research, published in the journal Environmental International, discovered that exposure to two common environmental contaminants, PFAS and PCBs, could increase the risk of the autoimmune disease.

PFAS, or per- and polyfluoroalkyl substances, known as “forever chemicals,” are used in some common household products, such as non-stick cookware, textiles and cleaning products. They have also been found in drinking water throughout the U.S., according to the U.S. Environmental Protection Agency.

COMMON CLEANING CHEMICAL TIED TO SPIKE IN LIVER DISEASE ACROSS US, RESEARCHERS SAY

Advertisement

PCBs, or polychlorinated biphenyls, are toxic industrial chemicals once widely used in electrical equipment before being banned decades ago, as stated by the National Institute of Environmental Health Sciences.

The new study findings were based on blood samples of 1,800 Swedish individuals, including about 900 who had recently been diagnosed with MS, according to a university press release.

PFAS, or per- and polyfluoroalkyl substances, known as “forever chemicals,” are used in some common household products, including non-stick cookware. (iStock)

The first phase of the trial studied 14 different PFAS contaminants and three substances that appear when PCBs are broken down in the body. These were then investigated for a link to the odds of diagnosis.

‘FOREVER CHEMICALS’ FOUND IN US DRINKING WATER, MAP SHOWS ‘HOT SPOTS’ OF HIGHEST LEVELS

Advertisement

“We saw that several individual substances, such as PFOS and two hydroxylated PCBs, were linked to increased odds for MS,” lead study author Kim Kultima said in a statement. “People with the highest concentrations of PFOS and PCBs had approximately twice the odds of being diagnosed with MS, compared to those with the lowest concentrations.”

The researchers then examined the combined effects of these substances and found that the mixture was also linked to increased risk.

CLICK HERE FOR MORE HEALTH STORIES

Fellow researcher Aina Vaivade noted that risk assessments should consider chemical mixtures, not just individual exposures, because people are typically exposed to multiple substances at the same time.

“We saw that several individual substances, such as PFOS and two hydroxylated PCBs, were linked to increased odds for MS,” the lead study author said. (iStock)

Advertisement

The final phase of the study investigated the relationship between inheritance, chemical exposure and the odds of MS diagnosis, revealing that those who carry a certain gene variant actually have a reduced MS risk.

However, individuals who carried the gene and had higher exposure to PFOS a singular type of chemical in the PFAS family had an “unexpected” increased risk of MS.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This indicates that there is a complex interaction between inheritance and environmental exposure linked to the odds of MS,” Kultima said. 

“We therefore think it is important to understand how environmental contaminants interact with hereditary factors, as this can provide new knowledge about the genesis of MS and could also be relevant for other diseases.”

Advertisement

Multiple sclerosis is a disease that leads to the breakdown of the protective covering of the nerves, according to Mayo Clinic. (iStock)

Fox News senior medical analyst Dr. Marc Siegel commented on these findings in an interview with Fox News Digital.

“MS is a complex disease that is somewhat autoimmune and somewhat post-inflammatory,” said Siegel, who was not involved in the study. “Epstein-Barr virus infection greatly increases the risk of MS.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“There is every reason to believe that environmental triggers play a role, including microplastics, and this important study shows a correlation, but not causation — in other words, it doesn’t prove that the microplastics caused MS.”

Advertisement

The study had some limitations, the researchers acknowledged, including that the chemical exposure was measured only once, at the time of blood sampling. This means it may not accurately represent participants’ long-term or past exposure levels relevant to MS development.

“There is every reason to believe that environmental triggers play a role.”

Fox News Digital reached out to several industry groups and manufacturers requesting comment on the potential link between PFAS chemicals and multiple sclerosis. 

Several have issued public statements, including the American Chemistry Council, which states on its website that “manufacturers and many users of today’s PFAS are implementing a variety of practices and technologies to help minimize environmental emissions.”

In April 2024, the EPA enacted a new federal rule that sets mandatory limits on certain PFAS chemicals in drinking water, aiming to reduce exposure. The agency also aims to fund testing and treatment efforts.

Advertisement

A woman working out outdoors takes a sip of water from a plastic bottle. (iStock)

Multiple sclerosis is a disease that leads to the breakdown of the protective coverings that surround nerve fibers, according to Mayo Clinic.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The immune system’s attack on these nerve sheaths can cause numbness, weakness, trouble walking and moving, vision changes and other symptoms, and can lead to permanent damage.

There is currently no cure for MS, Mayo Clinic reports, but treatment is available to manage symptoms and modify the course of the disease.

Advertisement

Continue Reading

Health

Natural Ozempic? 6 GLP-1 Foods That Work Just Like the Shot

Published

on

Natural Ozempic? 6 GLP-1 Foods That Work Just Like the Shot


Advertisement


6 GLP-1 Foods That Boost Weight Loss Naturally—No Injections Needed | Woman’s World




















Advertisement











Advertisement




Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Trending